Bullish & Foolish
Full CBIO fundamentals All 466 on the Survival Watch

CBIOCrescent Biopharma, Inc.

Is Crescent Biopharma struggling financially?

Yes, by its own account. Crescent Biopharma told the SEC on 21 Apr 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Apr 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$637.0M
Source filing
DEF 14A 21 Apr 2026
Balance sheet
30 Jun 2026

Cash runway

  • 24months

    If the burn speeds up

    Empty by Jun 2028

  • 33months

    If it eases off

    Empty by Mar 2029

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$171.6M

÷

Cash burned over the last 12 months

$72.5M

What Crescent Biopharma told the SEC

…EY was approved by the Audit Committee. Representatives of EY are not expected to attend the Annual Meeting. Except for an explanatory paragraph stating that substantial doubt exists about GlycoMimetics, Inc.’s ability to continue as a going concern as described in Note 2 to its financial statements, the reports of EY on the financial statements of GlycoMimetics for the fiscal years ended December 31, 2024 and 2023 did not contain…

Crescent Biopharma, Inc., Form DEF 14A, filed 21 Apr 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 99.8% share-count increase The company issued stock. Each share now owns 49.9% less of the business than a year ago, before any change in the price.
  • Cash burn is increasing It is spending 63% more cash per year than it was, so the runway above shortens even if nothing else changes.

Other Biotech/Pharma companies that filed the doubt